AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy.
In: PR Newswire, 2023-09-06
Zeitungsartikel
Zugriff:
Titel: |
AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy.
|
---|---|
Zeitschrift: | PR Newswire, 2023-09-06 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|